ClinicalTrials.gg
CompletedNCT02296411ELITRAUpdated Apr 22, 2026Results posted

Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)

A Phase 2 interventional study of CHF 5259 12.5 µg + Qvar and CHF 5259 placebo + Qvar in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 28 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing glycopyrrolate in Asthma — 1 open to participants now, 1 under way, none of them phase 3. Glycopyrrolate · Asthma.

Enrollment
4th of 10
98 · median 69
Started
2014
the only one that year
Phase 2
2 of 10
1 open now
Registered
2nd of 10
by date
Lead sponsor
3 of 10
Chiesi Farmaceutici S.p.A.

Among the 10 studies testing glycopyrrolate in Asthma, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 2, and was the 2nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 10 studies testing glycopyrrolate in Asthma is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing glycopyrrolate in Asthma, or all of them as a file.
02

Study summary

Primary objective

The primary objective was to evaluate the superiority of CHF 5259 (glycopyrronium bromide [GB]) in a pressurised metered dose inhaler (pMDI) (50 μg total daily dose) versus placebo in terms of forced expiratory volume in the first second (FEV1) area under the curve between time 0 and 12 hours (AUC0-12h) normalised by time on Day 42.

Key secondary objective

The key secondary objective was to evaluate the superiority of CHF 5259 pMDI (50 μg total daily dose) versus placebo in terms of peak FEV1 on Day 42.

Secondary objectives

The secondary objectives were:

  • To evaluate the effect of CHF 5259 pMDI on other lung function parameters and on clinical outcome measures;
  • To assess the safety and tolerability of study medications.
Read the detailed description

This was a phase IIb, multicentre, randomised, double-blind, placebo-controlled, 2-way crossover study consisting of two 6-week treatment periods (42 days each ±2 days), separated by a 1-week washout period (+2 days). The study employed a complete block design and a multiple-dosing regimen. It was designed as an add-on therapy to evaluate the efficacy and safety of CHF 5259 pMDI when used in combination with Qvar® pMDI in patients with uncontrolled asthma on low-to-medium doses of inhaled corticosteroids (ICS).

The crossover design was chosen because each patient serves as their own control, thereby reducing variability caused by inter-patient differences and minimizing the effects of potential confounding factors. This design improve statistical power, allowing for estimation of comparisons between treatments with a smaller sample size compared to a parallel arms study. The study aimed to randomise 98 patients to ensure at least 68 evaluable participants, accounting for an estimated 30% dropout or non-evaluable rate.

The study included the following phases:

  • Pre-Screening Phase (Visit [V] 0): Conducted within 7 days prior to the Screening Visit, this visit aimed to explain the study to potential participants, obtain informed consent, and instruct patients on procedures for the Screening Visit.
  • Screening Phase (Visit 1): This visit assessed eligibility for inclusion in the study and transitioned participants from their previous ICS therapy to a clinically equivalent dose of Qvar® pMDI (ranging from 50 μg to 400 μg daily). The Qvar® regimen was maintained as background therapy throughout the study. The Screening Visit was followed by a 2-week open-label run-in phase (±2 days) with Qvar® pMDI to ensure baseline standardization without compromising disease control.
  • Investigational Phase:

Comprised two treatment periods:

  1. Treatment Period 1 (P1): Spanning 42 days, starting at randomisation (Visit 2) and ending at Day 42 (Visit 3).
  2. Treatment Period 2 (P2): Spanning another 42 days, starting at Visit 4 (Day 1 of Period 2) and concluding at Visit 5 (Day 42 of Period 2).

During these periods, patients received two puffs of their assigned treatment (CHF 5259 or placebo) twice daily (morning and evening), in addition to their stable Qvar® therapy.

A 1-week washout period (+2 days) was implemented between the two treatment periods to minimize the potential for carryover effects from the first treatment period.

  • Follow-Up Phase: One week (+2 days) after the final treatment visit (Visit 5) or early termination, a follow-up phone call was conducted to assess unresolved adverse events (AEs) and document any new AEs or concomitant medications.

Overall, the study lasted 17 weeks per participant, including a 1-week pre-screening period; the 2-week run-in period; two 6-week treatment periods, and the follow-up phase. The two 6-week treatment periods allowed sufficient time for the evaluation of efficacy endpoints, while the 1-week washout period was deemed adequate to eliminate residual treatment effects.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma, Anticholinergics
  • Corticosteroids
  • CHF 5259 pMDI
  • Qvar® pMDI add-on therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient's written obtained prior to any study related procedures;
  2. Male or female patients aged ≥18 and ≤75 years;
  3. History of asthma ≥5 year and diagnosed before the age of 40 years;
  4. Patients with uncontrolled asthma on low medium doses of ICS (200 - 1000 μg daily dose BDP non-extrafine or estimated clinical comparable dose) at a stable dose for at least 4 weeks prior to Screening visit;
  5. Patients with a pre bronchodilator ≥40% and \<90% of their predicted normal value, after appropriate from bronchodilators, at Screening visit and the end of the run in period;
  6. Patients with a positive response to the reversibility test at Screening visit within 30 minutes after administration of 400 μg of salbutamol pMDI, defined as ΔFEV1 ≥12% and ≥200 mL over baseline; Note: In case this reversibility threshold was not met, the test could have been performed once before randomisation.
  7. Patients with uncontrolled asthma evidenced by a score at the Asthma Control Questionnaire® (ACQ) ≥1.5 (criterion had to be met at Screening visit and the end of the run in period);
  8. Patients with a co-operative attitude and ability to be trained to correctly use the pMDI and the electronic peak flow meter (e-peak flow meter). At the Screening visit (V1), all the above mentioned inclusion criteria were checked. At the Randomisation visit (V2), the following inclusion criteria were re checked: 5, 7 and 8.

Exclusion criteria

Exclusion Criteria:

  1. Inability to carry out pulmonary lung function testing, to comply with study procedures or with study medication intake;
  2. History of near fatal asthma or of a past hospitalisation for asthma in intensive care unit or of frequent exacerbations in the last year which, in the judgement of the Investigator, may have placed the patient at risk;
  3. Hospitalisation, emergency room admission or use of systemic for asthma exacerbation in the 4 weeks prior to Screening visit or during the run-in period;
  4. Lower respiratory tract infection in the 4 weeks before Screening visit or during the run-in period;
  5. Patients who were in current therapy for gastroesophageal reflux disease (GERD) or patients with a medical history of GERD that led to asthma symptoms;
  6. Patients with a seasonal worsening of asthma and who were not able to complete the study outside the relevant allergen season;
  7. History of cystic fibrosis, bronchiectasis or alpha 1 antitrypsin deficiency, bronco carcinoma, lung carcinoma or any other significant lung disease which may have interfered with data evaluation;
  8. Patients with a medical history or current diagnosis of as defined by the Global Initiative for chronic obstructive lung disease (GOLD) guidelines (2014);
  9. Current smokers or ex-smokers with total cumulative exposure equal or more than 10 pack years or having stopped smoking one year or less prior to Screening visit;
  10. Any change in dose, schedule or formulation of ICS in the 4 weeks prior to Screening visit;
  11. Patient had used any of the following treatments 4 weeks before Screening visit: inhaled LABAs, inhaled LAMAs, inhaled ICS/LABA fixed combinations, theophylline,leukotriene modifiers, cromolyn sodium, nedocromil sodium, systemic anticholinergics, systemic corticosteroids (12 weeks for slow release corticosteroids);
  12. Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of ) unless are using at least one or more of the following reliable methods of :

    1. Placement of an intrauterine device or intrauterine system;
    2. Hormonal contraception (implantable, injectable, patch, oral);
    3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical vaults/caps) with spermicidal foam/gel/film/cream/suppository;
    4. Male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate); Reliable contraception was maintained throughout the study and for 1 week after the last study dose. Pregnancy tests were performed at study entry (a serum test at Screening visit and a urinary test at Screening and Randomisation visits) in all women of childbearing potential.

    Any women (physiologic menopause defined as "12 consecutive months of amenorrhea") or women permanently sterilised (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) were enrolled in the study.

  13. Patients who received any new drug or participated in clinical study either within the last 8 weeks (or 5 half-lives for biologic products with slow elimination) before Screening visit;
  14. Patients who had (CS) cardiovascular condition according to Investigator's judgement such as but not limited to: congestive heart failure ( [NYHA] class >3), acute ischemic heart disease in the last year prior to study Screening, history of sustained cardiac arrhythmias or sustained and non-sustained cardiac arrhythmias diagnosed in the last 6 months (sustained means lasting more than 30 seconds or ending only with external action, or leads to hemodynamic collapse; non-sustained means >5 beats \<30 seconds), impulse conduction blocks. Similarly, patients affected by permanent or paroxysmal atrial fibrillation were not considered for enrolment;
  15. An abnormal and CS 12-lead (ECG) that resulted in active medical problem which may have impacted the safety of the patient according to Investigator's judgement;
  16. Patients whose electrocardiogram (12-lead ECG) showed Fridericia (QTcF) >450 ms for males or QTcF >470 ms for females at Screening or at Randomisation visits;
  17. Medical diagnosis of narrow angle glaucoma, clinically relevant prostatic hypertrophy or bladder neck obstruction that, in the opinion of the Investigator, prevented use of anticholinergic agents;
  18. Unstable concurrent disease: e.g. uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; with moderate to severe renal impairment (known of ≤50 mL/min); uncontrolled gastrointestinal disease (e.g. active peptic ulcer); uncontrolled neurological disease; uncontrolled haematological disease; uncontrolled disorders, or other laboratory abnormality that may have increased the risk associated with study participation or study medications administration and, in the judgment of theInvestigator, made the patient inappropriate for entry into this study, or placed the patients at undue risk or potentially compromised the results or interpretation of the study;
  19. Patients having received a within two weeks prior to Screening or during the run-in (inactivated influenza vaccination was acceptable provided it was not administered less than 48 hours prior to Screening);
  20. Patients mentally or legally incapacitated;
  21. Patients with a history of alcohol or drug abuse;
  22. Patients with known intolerance/ or contra indication to treatment with β2 agonists, inhaled corticosteroids, anti cholinergics or propellant gases/;
  23. Patients with major surgery in the 3 months prior to Screening visit or planned surgery during the trial;
  24. Patients treated with anti IgE antibodies;
  25. Patients treated with non-potassium sparing diuretics (unless administered as a FDC with a potassium conserving drug), non-selective beta blocking drugs (except if taken at stable regimen for at least 2 months before Screening), quinidine, quinidine like anti arrhythmics, or any medication with a QTc prolongation potential or a history of QTc prolongation;
  26. Patients treated with monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants;
  27. Patients who are receiving any therapy that could have interfered with the study medications according to Investigator's opinion. At the Screening visit (V1), all the above mentioned exclusion criteria were checked. At the Randomisation visit (V2), the following exclusion criteria were re-checked: 1, 2, 3, 4, 5, 12, 15, 16, 18, 19, 23 and 27.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
98 participants (actual)

Study arms

  • Other
    sequence CHF 5259 pMDI - placebo pMDI + Qvar

    In this sequence, patients received: CHF 5259 pMDI (Active Treatment): CHF 5259 pMDI 12.5 µg as two puffs twice daily (b.i.d.), for a total daily dose of 50 µg, administered via metered dose inhalation of pressurised solution using a standard actuator. Treatment duration: 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg. Wash-Out Period (1 Week): Qvar® pMDI 50 µg or 100 µg b.i.d., administered via metered dose inhalation of pressurised solution, with a daily dose ranging from 100 µg to 400 µg. Placebo of CHF 5259 pMDI (Control Treatment): A matched placebo for CHF 5259 pMDI, administered via metered dose inhalation of pressurised solution using a standard actuator. Treatment duration: 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg.

    Drug: CHF 5259 12.5 µg + Qvar · Drug: CHF 5259 placebo + Qvar

  • Other
    sequence placebo pMDI - CHF 5259 pMDI + Qvar

    In this sequence, patients received: Placebo of CHF 5259 pMDI (Control Treatment): A matched placebo for CHF 5259 pMDI, administered via metered dose inhalation using a standard actuator for 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg. Wash-Out Period (1 Week): Qvar® pMDI 50 µg or 100 µg b.i.d., administered via metered dose inhalation using a standard actuator, with a daily dose ranging from 100 µg to 400 µg. CHF 5259 pMDI (Active Treatment): CHF 5259 pMDI 12.5 µg as two puffs twice daily (b.i.d.), for a total daily dose of 50 µg, administered via metered dose inhalation using a standard actuator for 6 weeks (±2 days). Qvar® pMDI 50 µg or 100 µg b.i.d. was provided as background therapy, with a daily dose ranging from 100 µg to 400 µg.

    Drug: CHF 5259 12.5 µg + Qvar · Drug: CHF 5259 placebo + Qvar

Interventions

  • DrugCHF 5259 12.5 µg + Qvar

    Drug page: Glycopyrrolate

    comparison of CHF 5259 versus placebo over 2 treatment periods of 6 weeks ± 2 days

    Also known as: glycopyrrolate bromide

  • DrugCHF 5259 placebo + Qvar

    comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks ± 2 days

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. FEV1 AUC0-12h Normalized by Time on Day 42 (ITT Population)

    FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at Day 42 post-dose.

    Time frame: Day 42

  2. FEV1 AUC0-12h Normalized by Time on Day 42 (PP Population)

    FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at Day 42 post-dose.

    Time frame: Day 42

Secondary outcomes

  1. Change From Baseline in Peak FEV1 on Day 42 (ITT Population)

    The change from baseline to Day 42 in Forced Expiratory Volume in the first second (FEV1) peak is a key secondary variable.

    Time frame: Baseline and Day 42

  2. Change From Baseline in Peak FEV1 on Day 42 (PP Population)

    The change from baseline to Day 42 in Forced Expiratory Volume in the first second (FEV1) peak is a key secondary variable.

    Time frame: Baseline and Day 42

  3. FEV1 AUC0-12h Normalized by Time on Day 1

    FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose on Day 1 post-dose.

    Time frame: Day 1

  4. FEV1 AUC0-3h Normalised by Time on Day 1

    AUC0-3h =Area Under the Curve between time 0 and 3 hours. FEV1 was assessed at 15 min, 30 min, 45 min, 1h, 2h, 3h on day 1.

    Time frame: Day 1

  5. FEV1 AUC0-3h Normalised by Time on Day 42

    AUC0-3h =Area Under the Curve between time 0 and 3 hours. FEV1 was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h. on day 1 and on day 42

    Time frame: Day 42

  6. Change From Baseline in Peak FEV1 on Day 1

    The peak FEV1 is determined as the maximum FEV1 value obtained between 15 minutes and 12 hours post-dose. The baseline value is the mean of the pre-dose measurement of FEV1 at Day 1 of each treatment period.

    Time frame: Baseline and Day 1

  7. Change From Baseline in Pre-dose Morning Through FEV1 on Day 42

    The pre-dose morning FEV1 is defined as the mean of the two measurements at 45 and 15 minutes predose.

    Time frame: Baseline and Day 42

  8. Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 1

    Baseline value is the average of the pre-dose measurements of FEV1 Percentage of Predicted Normal Value on Day 1 of each treatment period. FEV1 Percentage Predicted Normal values was measured at all post-dose Time Points (T15´: 15 min post-dose, T30´: 30 min post-dose, T45´: 45 min post-dose, T1H: 1 hour post-dose ,T2H: 2 hours post-dose, T2H: 3 hours post-dose,T4H: 4 hours post-dose ,T6H: 6 hours post-dose ,T8H: 8 hours post-dose, T11H30´: 11 hours and 30 minpost-dose, T12H: 12 hours post-dose). Hereunder only changes from baseline at 12h post-dose data are reported.

    Time frame: Baseline and Day 1

  9. Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 42

    Baseline value is the average of the pre-dose measurements of FEV1 Percentage of Predicted Normal Value on Day 1 of each treatment period. FEV1 Percentage Predicted Normal values was measured at all post-dose Time Points (T15´: 15 min post-dose, T30´: 30 min post-dose, T45´: 45 min post-dose, T1H: 1 hour post-dose ,T2H: 2 hours post-dose, T2H: 3 hours post-dose,T4H: 4 hours post-dose ,T6H: 6 hours post-dose ,T8H: 8 hours post-dose, T11H30´: 11 hours and 30 minpost-dose, T12H: 12 hours post-dose). Hereunder only changes from baseline at 12h post-dose data are reported.

    Time frame: Baseline and Day 42

  10. Average Daily PEF (Morning and Evening) During Treatment Periods

    PEF = Peak Expiratory Flow. PEF was measured at home by patients using a portable e-peak flow meter (AM3 device). Patients were educated on the purpose and technique of PEF home monitoring and specific instructions for use were made available to them. During the run-in/wash-out and the two treatment periods (from V1 to V5), PEF was monitored twice daily, in the morning and in the evening, before the intake of the background medication or study medication. PEF was also assessed during the visits only for information purpose of the Investigator. During each measurement session, the patient performed 3 blows and data were recorded in the device. The average daily morning PEF is the mean value of all morning PEF measurements. The average daily evening PEF is the mean value of all evening PEF measurements. Please note: the average daily morning PEF and the average daily evening PEF during the treatment periods are reported.

    Time frame: Twice Daily during treatment periods (from V1 to V5)

  11. Average Daily Asthma Symptoms (Daytime) During Treatment Periods

    Asthma symptoms (cough, wheeze, chest tightness and breathlessness) were scored, always before PEF measurements, twice daily - daytime and nighttime - as follows: Daytime asthma symptom score (ranging 0-3, where the lower the score the better the outcome): 0 = No symptom 1. = Mild: aware of symptoms which can be easily tolerated 2. = Moderate: discomfort causing interference with daily activity 3. = Severe: inability to work/make usual activity The average score of each symptom is the mean value of all measurements. Total average Daily Asthma Symptoms score daytime = Σ〖Cough daytime score + Wheeze daytime score + Chest Tightness daytime score * Breathlessness daytime score〗/ Number of days with available data. The sum of the four symptoms per day ranges from 0 (no symptoms) to 12 (maximum severity), and the average total score across days retains this range, reflecting mean symptom severity. A lower score indicates better symptom control.

    Time frame: During treatment periods (from V2 to V5), up to 6 weeks

  12. Average Daily Asthma Symptoms (Nighttime) During Treatment Periods

    Asthma symptoms (cough, wheeze, chest tightness and breathlessness) were scored, always before PEF measurements, twice daily - daytime and nighttime - as follows: Nighttime asthma symptom score (ranging 0-3, where the lower the score the better the outcome): 0 = No symptom 1. = Mild: symptoms not causing awakening 2. = Moderate: discomfort causing awakenings 3. = Severe: causing awakenings for most of the night / don't allow to sleep at all The average score of each symptom is the mean value of all measurements. Total average Daily Asthma Symptoms score nighttime = Σ〖Cough nighttime score + Wheeze nighttime score + Chest Tightness nighttime score + Breathlessness nighttime score〗/ Number of days with available data. The sum of the four symptoms per day ranges from 0 (no symptoms) to 12 (maximum severity), and the average total score across days retains this range, reflecting mean symptom severity. A lower score indicates better symptom control.

    Time frame: Daily during treatment periods (from V2 to V5)

  13. Percentage of Asthma Control Days During the Treatment Periods

    An asthma control day is derived from patient diary data, and is defined as days on which the patient meets both of the following criteria: a total asthma symptom score (daytime + nighttime) of 0, indicating no symptoms such as cough, wheeze, chest tightness, or breathlessness, and no use of rescue medication during the day.The percentage of control days is calculated as the number of asthma control days / number of days with available data.

    Time frame: During the treatment periods (from V2 to V5)

  14. Average Use of Rescue Medication (Number of Puffs/Day)

    The average use of rescue medication is expressed as the number of puffs per day and the number of times per day. The most common rescue medication used is salbutamol: the number of salbutamol puffs and the number of times salbutamol is used were recorded in the electronic diary twice daily, in the morning and in the evening, before the PEF measurements. Hereunder the first parameter is reported.

    Time frame: During the treatment periods (from V2 to V5)

  15. Average Use of Rescue Medication (Number of Times/Day)

    The average use of rescue medication is expressed as the number of puffs per day and the number of times per day. The most common rescue medication used is salbutamol: the number of salbutamol puffs and the number of times salbutamol is used were recorded in the electronic diary twice daily, in the morning and in the evening, before the PEF measurements. Hereunder the second parameter is reported.

    Time frame: During the treatment periods (from V2 to V5)

  16. Change From Baseline in Asthma Control Questionnaire (ACQ) Total Score on Day 42

    The ACQ is a validated questionnaire rating patient asthma control. It has a multidimensional construct assessing symptoms (5 questions-self-administered) and rescue bronchodilator use (1 question-self-administered), and FEV1% predicted (1 question answered by clinicians). For each of the 7 questions, possible answer could score from 0 (no impairment for symptoms and rescue use) to 6 (maximum impairment for symptoms and rescue use). The questions are equally weighted and the ACQ total score is the mean of the 7 questions and therefore between 0 (asthma totally controlled) and 6 (asthma severely uncontrolled).

    Time frame: Baseline and Day 42

  17. Change From Baseline in FVC on Day 1

    FVC = Forced Vital Capacity. FVC was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at both days. The baseline value is the mean of the pre-dose measurement of FVC at Day 1 of each treatment period. Only changes from baseline at 12h post-dose data are reported hereunder.

    Time frame: Baseline and Day 1

  18. Change From Baseline in FVC on Day 42

    FVC = Forced Vital Capacity. FVC was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at both days. The baseline value is the mean of the pre-dose measurement of FVC at Day 1 of each treatment period. Only changes from baseline at 12h post-dose data are reported hereunder.

    Time frame: Baseline and Day 42

07

Results

Posted Apr 22, 2026

Participant flow

A total of 138 patients were screened, with 98 patients randomised to one of the following two treatment sequence groups: * CHF 5259 pMDI - placebo: n = 50 * Placebo - CHF 5259 pMDI: n = 48

Participant flow — Overall Study
MilestoneCHF5259 pMDI - Placebo pMDI SequencePlacebo pMDI - CHF 5259 pMDI
Started5048
Completed5047
Not completed01
Withdrew: Protocol violation01

Outcome measures

PrimaryFEV1 AUC0-12h Normalized by Time on Day 42 (ITT Population)

FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at Day 42 post-dose.

Time frame:
Day 42
Reported as:
Mean · liters
FEV1 AUC0-12h Normalized by Time on Day 42 (ITT Population)
litersCHF5259 pMDI - ITTPlacebo pMDI - ITT
FEV1 AUC0-12h Normalized by Time on Day 42 (ITT Population)2.470 ± 0.8572.373 ± 0.830
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = <0.001 · Adjusted mean difference: 0.135 · 95% CI 0.092 to 0.177
PrimaryFEV1 AUC0-12h Normalized by Time on Day 42 (PP Population)

FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at Day 42 post-dose.

Time frame:
Day 42
Reported as:
Mean · liters
FEV1 AUC0-12h Normalized by Time on Day 42 (PP Population)
litersCHF5259 pMDIPlacebo pMDI
FEV1 AUC0-12h Normalized by Time on Day 42 (PP Population)2.480 ± 0.8492.365 ± 0.827
Statistical analysis
  • CHF5259 pMDI vs Placebo pMDI · ANCOVA · p = <0.001 · Adjusted mean difference: 0.128 · 95% CI 0.082 to 0.174
SecondaryChange From Baseline in Peak FEV1 on Day 42 (ITT Population)

The change from baseline to Day 42 in Forced Expiratory Volume in the first second (FEV1) peak is a key secondary variable.

Time frame:
Baseline and Day 42
Reported as:
Mean · liters
Change From Baseline in Peak FEV1 on Day 42 (ITT Population)
litersCHF5259 pMDI - ITTPlacebo pMDI - ITT
Change From Baseline in Peak FEV1 on Day 42 (ITT Population)0.394 ± 0.2810.278 ± 0.293
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = <0.001 · Adjusted mean difference: 0.137 · 95% CI 0.094 to 0.18
SecondaryChange From Baseline in Peak FEV1 on Day 42 (PP Population)

The change from baseline to Day 42 in Forced Expiratory Volume in the first second (FEV1) peak is a key secondary variable.

Time frame:
Baseline and Day 42
Reported as:
Mean · liters
Change From Baseline in Peak FEV1 on Day 42 (PP Population)
litersCHF5259 pMDIPlacebo pMDI
Change From Baseline in Peak FEV1 on Day 42 (PP Population)0.392 ± 0.2630.258 ± 0.299
Statistical analysis
  • CHF5259 pMDI vs Placebo pMDI · ANCOVA · p = <0.001 · Adjusted mean difference: 0.144 · 95% CI 0.098 to 0.191
SecondaryFEV1 AUC0-12h Normalized by Time on Day 1

FEV1 = Forced Expiratory Volume in the first second AUC0-12h = area under the curve between time 0 and 12 hours; assessments were made at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose on Day 1 post-dose.

Time frame:
Day 1
Reported as:
Mean · liters
FEV1 AUC0-12h Normalized by Time on Day 1
litersCHF5259 pMDI - ITTPlacebo pMDI - ITT
FEV1 AUC0-12h Normalized by Time on Day 12.482 ± 0.8622.356 ± 0.835
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = <0.001 · Adjusted mean difference: 0.115 · 95% CI 0.074 to 0.155
SecondaryFEV1 AUC0-3h Normalised by Time on Day 1

AUC0-3h =Area Under the Curve between time 0 and 3 hours. FEV1 was assessed at 15 min, 30 min, 45 min, 1h, 2h, 3h on day 1.

Time frame:
Day 1
Reported as:
Mean · liters
FEV1 AUC0-3h Normalised by Time on Day 1
litersCHF5259 pMDI - ITTPlacebo pMDI - ITT
FEV1 AUC0-3h Normalised by Time on Day 12.496 ± 0.8632.344 ± 0.815
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = <0.001 · Adjusted mean difference: 0.143 · 95% CI 0.099 to 0.187
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = <0.001 (The FEV1 AUC0-3h normalised by time was analysed by means of an ANCOVA model with treatment, patient and period as fixed effects and baseline FEV1 (mean of of pre-dose measurements of FEV1 at Day 1) as a covariate.) · Adjusted mean difference: 0.151 · 95% CI 0.101 to 0.201
SecondaryFEV1 AUC0-3h Normalised by Time on Day 42

AUC0-3h =Area Under the Curve between time 0 and 3 hours. FEV1 was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h. on day 1 and on day 42

Time frame:
Day 42
Reported as:
Mean · liters
FEV1 AUC0-3h Normalised by Time on Day 42
litersCHF5259 pMDI - ITTPlacebo pMDI - ITT
FEV1 AUC0-3h Normalised by Time on Day 422.498 ± 0.8702.357 ± 0.839
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = <0.001 · Adjusted mean difference: 0.151 · 95% CI 0.101 to 0.201
SecondaryChange From Baseline in Peak FEV1 on Day 1

The peak FEV1 is determined as the maximum FEV1 value obtained between 15 minutes and 12 hours post-dose. The baseline value is the mean of the pre-dose measurement of FEV1 at Day 1 of each treatment period.

Time frame:
Baseline and Day 1
Reported as:
Mean · liters
Change From Baseline in Peak FEV1 on Day 1
litersCHF5259 pMDI - ITTPlacebo pMDI - ITT
Change From Baseline in Peak FEV1 on Day 10.384 ± 0.2480.286 ± 0.237
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = <0.001 · Adjusted mean difference: 0.112 · 95% CI 0.071 to 0.154
SecondaryChange From Baseline in Pre-dose Morning Through FEV1 on Day 42

The pre-dose morning FEV1 is defined as the mean of the two measurements at 45 and 15 minutes predose.

Time frame:
Baseline and Day 42
Reported as:
Mean · liters
Change From Baseline in Pre-dose Morning Through FEV1 on Day 42
litersCHF5259 pMDI - ITTPlacebo pMDI - ITT
Change From Baseline in Pre-dose Morning Through FEV1 on Day 420.136 ± 0.2910.041 ± 0.258
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = <0.001 (The changes from baseline in pre-dose morning FEV1 were analysed by means of an ANCOVA model with treatment, patient and period as fixed effects and baseline FEV1 (mean of the pre-dose measurements of FEV1 at Day 1) as a covariate.) · Adjusted mean difference: 0.112 · 95% CI 0.061 to 0.164
SecondaryChange From Baseline in FEV1 Percentage of Predicted Normal Value on Day 1

Baseline value is the average of the pre-dose measurements of FEV1 Percentage of Predicted Normal Value on Day 1 of each treatment period. FEV1 Percentage Predicted Normal values was measured at all post-dose Time Points (T15´: 15 min post-dose, T30´: 30 min post-dose, T45´: 45 min post-dose, T1H: 1 hour post-dose ,T2H: 2 hours post-dose, T2H: 3 hours post-dose,T4H: 4 hours post-dose ,T6H: 6 hours post-dose ,T8H: 8 hours post-dose, T11H30´: 11 hours and 30 minpost-dose, T12H: 12 hours post-dose). Hereunder only changes from baseline at 12h post-dose data are reported.

Time frame:
Baseline and Day 1
Reported as:
Mean · percentage of predicted FEV1
Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 1
percentage of predicted FEV1CHF5259 pMDI - ITTPlacebo pMDI - ITT
Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 15.1 ± 8.12.9 ± 7.5
SecondaryChange From Baseline in FEV1 Percentage of Predicted Normal Value on Day 42

Baseline value is the average of the pre-dose measurements of FEV1 Percentage of Predicted Normal Value on Day 1 of each treatment period. FEV1 Percentage Predicted Normal values was measured at all post-dose Time Points (T15´: 15 min post-dose, T30´: 30 min post-dose, T45´: 45 min post-dose, T1H: 1 hour post-dose ,T2H: 2 hours post-dose, T2H: 3 hours post-dose,T4H: 4 hours post-dose ,T6H: 6 hours post-dose ,T8H: 8 hours post-dose, T11H30´: 11 hours and 30 minpost-dose, T12H: 12 hours post-dose). Hereunder only changes from baseline at 12h post-dose data are reported.

Time frame:
Baseline and Day 42
Reported as:
Mean · percentage of predicted normal value
Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 42
percentage of predicted normal valueCHF5259 pMDI - ITTPlacebo pMDI - ITT
Change From Baseline in FEV1 Percentage of Predicted Normal Value on Day 425.8 ± 8.92.9 ± 8.5
SecondaryAverage Daily PEF (Morning and Evening) During Treatment Periods

PEF = Peak Expiratory Flow. PEF was measured at home by patients using a portable e-peak flow meter (AM3 device). Patients were educated on the purpose and technique of PEF home monitoring and specific instructions for use were made available to them. During the run-in/wash-out and the two treatment periods (from V1 to V5), PEF was monitored twice daily, in the morning and in the evening, before the intake of the background medication or study medication. PEF was also assessed during the visits only for information purpose of the Investigator. During each measurement session, the patient performed 3 blows and data were recorded in the device. The average daily morning PEF is the mean value of all morning PEF measurements. The average daily evening PEF is the mean value of all evening PEF measurements. Please note: the average daily morning PEF and the average daily evening PEF during the treatment periods are reported.

Time frame:
Twice Daily during treatment periods (from V1 to V5)
Reported as:
Mean · liters/min
Average Daily PEF (Morning and Evening) During Treatment Periods
liters/minCHF5259 pMDI - ITTPlacebo pMDI - ITT
average daily morning363.2 ± 117.7346.9 ± 111.5
average daily evening372.4 ± 117355.5 ± 110.5
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANOVA · p = <0.001 · Adjusted mean difference: 14.2 · 95% CI 7.8 to 20.6
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANOVA · p = <0.001 · Adjusted mean difference: 14.7 · 95% CI 8.3 to 21.0
SecondaryAverage Daily Asthma Symptoms (Daytime) During Treatment Periods

Asthma symptoms (cough, wheeze, chest tightness and breathlessness) were scored, always before PEF measurements, twice daily - daytime and nighttime - as follows: Daytime asthma symptom score (ranging 0-3, where the lower the score the better the outcome): 0 = No symptom 1. = Mild: aware of symptoms which can be easily tolerated 2. = Moderate: discomfort causing interference with daily activity 3. = Severe: inability to work/make usual activity The average score of each symptom is the mean value of all measurements. Total average Daily Asthma Symptoms score daytime = Σ〖Cough daytime score + Wheeze daytime score + Chest Tightness daytime score * Breathlessness daytime score〗/ Number of days with available data. The sum of the four symptoms per day ranges from 0 (no symptoms) to 12 (maximum severity), and the average total score across days retains this range, reflecting mean symptom severity. A lower score indicates better symptom control.

Time frame:
During treatment periods (from V2 to V5), up to 6 weeks
Reported as:
Mean · score on a scale
Average Daily Asthma Symptoms (Daytime) During Treatment Periods
score on a scaleCHF5259 pMDI - ITTPlacebo pMDI - ITT
Average Daily Asthma Symptoms (Daytime) During Treatment Periods2.62 ± 1.982.66 ± 1.84
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = = 0.608 · Adjusted mean difference: -0.04 · 95% CI -0.21 to 0.12
SecondaryAverage Daily Asthma Symptoms (Nighttime) During Treatment Periods

Asthma symptoms (cough, wheeze, chest tightness and breathlessness) were scored, always before PEF measurements, twice daily - daytime and nighttime - as follows: Nighttime asthma symptom score (ranging 0-3, where the lower the score the better the outcome): 0 = No symptom 1. = Mild: symptoms not causing awakening 2. = Moderate: discomfort causing awakenings 3. = Severe: causing awakenings for most of the night / don't allow to sleep at all The average score of each symptom is the mean value of all measurements. Total average Daily Asthma Symptoms score nighttime = Σ〖Cough nighttime score + Wheeze nighttime score + Chest Tightness nighttime score + Breathlessness nighttime score〗/ Number of days with available data. The sum of the four symptoms per day ranges from 0 (no symptoms) to 12 (maximum severity), and the average total score across days retains this range, reflecting mean symptom severity. A lower score indicates better symptom control.

Time frame:
Daily during treatment periods (from V2 to V5)
Reported as:
Mean · score on a scale
Average Daily Asthma Symptoms (Nighttime) During Treatment Periods
score on a scaleCHF5259 pMDI - ITTPlacebo pMDI - ITT
Average Daily Asthma Symptoms (Nighttime) During Treatment Periods2.35 ± 2.12.39 ± 2.0
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = = 0.435 · Adjusted mean difference: -0.07 · 95% CI -0.23 to 0.1
SecondaryPercentage of Asthma Control Days During the Treatment Periods

An asthma control day is derived from patient diary data, and is defined as days on which the patient meets both of the following criteria: a total asthma symptom score (daytime + nighttime) of 0, indicating no symptoms such as cough, wheeze, chest tightness, or breathlessness, and no use of rescue medication during the day.The percentage of control days is calculated as the number of asthma control days / number of days with available data.

Time frame:
During the treatment periods (from V2 to V5)
Reported as:
Mean · percentage of days
Percentage of Asthma Control Days During the Treatment Periods
percentage of daysCHF5259 pMDI - ITTPlacebo pMDI - ITT
Percentage of Asthma Control Days During the Treatment Periods21.7 ± 32.319.4 ± 28.5
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANOVA · p = = 0.188 · Adjusted mean difference: 2.5 · 95% CI -1.2 to 6.2
SecondaryAverage Use of Rescue Medication (Number of Puffs/Day)

The average use of rescue medication is expressed as the number of puffs per day and the number of times per day. The most common rescue medication used is salbutamol: the number of salbutamol puffs and the number of times salbutamol is used were recorded in the electronic diary twice daily, in the morning and in the evening, before the PEF measurements. Hereunder the first parameter is reported.

Time frame:
During the treatment periods (from V2 to V5)
Reported as:
Mean · number of puffs/day
Average Use of Rescue Medication (Number of Puffs/Day)
number of puffs/dayCHF5259 pMDI - ITTPlacebo pMDI - ITT
Average Use of Rescue Medication (Number of Puffs/Day)1 ± 1.61.1 ± 1.5
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANOVA · p = = 0.462 · Adjusted mean difference: 0.0 · 95% CI -0.2 to 0.1
SecondaryAverage Use of Rescue Medication (Number of Times/Day)

The average use of rescue medication is expressed as the number of puffs per day and the number of times per day. The most common rescue medication used is salbutamol: the number of salbutamol puffs and the number of times salbutamol is used were recorded in the electronic diary twice daily, in the morning and in the evening, before the PEF measurements. Hereunder the second parameter is reported.

Time frame:
During the treatment periods (from V2 to V5)
Reported as:
Mean · number of times/day
Average Use of Rescue Medication (Number of Times/Day)
number of times/dayCHF5259 pMDI - ITTPlacebo pMDI - ITT
Average Use of Rescue Medication (Number of Times/Day)0.8 ± 1.40.9 ± 1.3
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANOVA · p = = 0.379 · Adjusted mean difference: 0.0 · 95% CI -0.1 to 0.0
SecondaryChange From Baseline in Asthma Control Questionnaire (ACQ) Total Score on Day 42

The ACQ is a validated questionnaire rating patient asthma control. It has a multidimensional construct assessing symptoms (5 questions-self-administered) and rescue bronchodilator use (1 question-self-administered), and FEV1% predicted (1 question answered by clinicians). For each of the 7 questions, possible answer could score from 0 (no impairment for symptoms and rescue use) to 6 (maximum impairment for symptoms and rescue use). The questions are equally weighted and the ACQ total score is the mean of the 7 questions and therefore between 0 (asthma totally controlled) and 6 (asthma severely uncontrolled).

Time frame:
Baseline and Day 42
Reported as:
Mean · score on a scale
Change From Baseline in Asthma Control Questionnaire (ACQ) Total Score on Day 42
score on a scaleCHF5259 pMDI - ITTPlacebo pMDI - ITT
Change From Baseline in Asthma Control Questionnaire (ACQ) Total Score on Day 42-0.39 ± 0.59-0.17 ± 0.56
Statistical analysis
  • CHF5259 pMDI - ITT vs Placebo pMDI - ITT · ANCOVA · p = = 0.026 · Adjusted mean difference: -0.16 · 95% CI -0.31 to -0.02
SecondaryChange From Baseline in FVC on Day 1

FVC = Forced Vital Capacity. FVC was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at both days. The baseline value is the mean of the pre-dose measurement of FVC at Day 1 of each treatment period. Only changes from baseline at 12h post-dose data are reported hereunder.

Time frame:
Baseline and Day 1
Reported as:
Mean · liters
Change From Baseline in FVC on Day 1
litersCHF5259 pMDI - ITTPlacebo pMDI - ITT
Change From Baseline in FVC on Day 10.105 ± 0.3480.114 ± 0.319
SecondaryChange From Baseline in FVC on Day 42

FVC = Forced Vital Capacity. FVC was measured at 15 min, 30 min, 45 min, 1h, 2h, 3h, 4h, 6h, 8h, 11.5h and 12h post-dose at both days. The baseline value is the mean of the pre-dose measurement of FVC at Day 1 of each treatment period. Only changes from baseline at 12h post-dose data are reported hereunder.

Time frame:
Baseline and Day 42
Reported as:
Mean · liters
Change From Baseline in FVC on Day 42
litersCHF5259 pMDI - ITTPlacebo pMDI - ITT
Change From Baseline in FVC on Day 420.096 ± 0.340.068 ± 0.346

Adverse events

Collected over AEs were collected from screening (Visit 1, D-14) to follow-up (Visit 6, week 14), or, in case, at early termination (EOT). Please note that AEs and overall mortality presented hereunder represent the safety set (i.e. all patients receiving any amount of study drug, including both run-in and randomized patients). As per planned analysis, AEs were collected in a combined manner: i.e. data on the run-in phase were combined with the ones of the reported arms.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in and Randomized CHF5259 pMDI (Safety Population)0/97 (0%)0/97 (0%)13/97 (13.4%)
Run-in and Randomized Placebo pMDI (Safety Population)0/98 (0%)0/98 (0%)11/98 (11.2%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventRun-in and Randomized CHF5259 pMDI (Safety Population)Run-in and Randomized Placebo pMDI (Safety Population)
NasopharyngitisInfections and infestations4/973/98
Weight increasedInvestigations2/970/98
InfluenzaInfections and infestations1/970/98
PeriodontitisInfections and infestations1/970/98
Skin bacterial infectionInfections and infestations1/970/98
Blood pressure increasedInvestigations1/970/98
Hepatic steatosisHepatobiliary disorders1/971/98
NeuritisNervous system disorders1/970/98
Sinus tachycardiaCardiac disorders1/970/98
Eye irritationEye disorders1/970/98

Baseline characteristics

ITT population: All randomised patients who received at least one dose of the study medication and with at least one available evaluation of efficacy after the baseline were included in the ITT population. Above demographics, all the efficacy variables were analysed based on the ITT population.

Age, Categorical
Age, Categorical(Participants)Sequence CHF 5259 pMDI - Placebo pMDI + QvarSequence Placebo pMDI - CHF 5259 pMDI + QvarTotal
<=18 years000
Between 18 and 65 years454489
>=65 years549
Age, Continuous
Age, Continuous(years)Sequence CHF 5259 pMDI - Placebo pMDI + QvarSequence Placebo pMDI - CHF 5259 pMDI + QvarTotal
Mean48.8 ± 14.047.2 ± 12.848.0 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Sequence CHF 5259 pMDI - Placebo pMDI + QvarSequence Placebo pMDI - CHF 5259 pMDI + QvarTotal
Female303161
Male201737
Region of Enrollment
Region of Enrollment(participants)Sequence CHF 5259 pMDI - Placebo pMDI + QvarSequence Placebo pMDI - CHF 5259 pMDI + QvarTotal
Netherlands011
Poland171936
Italy112
Bulgaria181937
Germany14822
08

Study locations

28 sites
  • Chiesi Clinical Trial Site 0107
    Rousse, 7002, Bulgaria
  • Chiesi Clinical Trial Site 0106
    Sevlievo, 5400, Bulgaria
  • Chiesi Clinical Trial Site 0101
    Sofia, 1000, Bulgaria
  • Chiesi Clinical Trial Site 0109
    Sofia, 1336, Bulgaria
  • Chiesi Clinical Trial Site 0108
    Sofia, 1407, Bulgaria
  • Chiesi Clinical Trial Site 0102
    Sofia, 1431, Bulgaria
  • Chiesi Clinical Trial Site 0103
    Sofia, 1431, Bulgaria
  • Chiesi Clinical Trial Site 0201
    Berlin, D-12165, Germany
  • Chiesi Clinical Trial Site 0203
    Leipzig, 04207, Germany
  • Chiesi Clinical Trial Site 0202
    Leipzig, 04357, Germany
  • Chiesi Clinical Trial Site 0206
    Magdeburg, 39112, Germany
  • Chiesi Clinical Trial Site 0207
    Radebeul, 01445, Germany
  • Chiesi Clinical Trial Site 0208
    Witten, 58452, Germany
  • Chiesi Clinical Trial Site 0306
    Brescia, 25123, Italy
  • Chiesi Clinical Trial Site 0301
    Pisa, 56124, Italy
  • Chiesi Clinical Trial Site 0304
    Pisa, 56124, Italy
  • Chiesi Clinical Trial Site 0303
    Pordenone, 33170, Italy
  • Chiesi Clinical Trial Site 0404
    Assen, 9401 RK, Netherlands
  • Chiesi Clinical Trial Site 0405
    Helmond, 5707 HA, Netherlands
  • Chiesi Clinical Trial Site 0501
    Bialystok, 15-010, Poland
  • Chiesi Clinical Trial Site 0502
    Bialystok, 15-351, Poland
  • Chiesi Clinical Trial Site 0503
    Elblag, 82-300, Poland
  • Chiesi Clinical Trial Site 0507
    Krakow, 30-349, Poland
  • Chiesi Clinical Trial Site 0504
    Krakow, 31-011, Poland
  • Chiesi Clinical Trial Site 0512
    Lodz, 90-141, Poland
  • Chiesi Clinical Trial Site 0510
    Lodz, 90-252, Poland
  • Chiesi Clinical Trial Site 0505
    Wroclaw, 53-310, Poland
  • Chiesi Clinical Trial Site 0506
    Zgierz, 95-100, Poland
09

References and documents

Individual participant data

Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Access criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Data sharing details ↗ · www.chiesi.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Aug 2015, 8 months.

Results were first posted in Apr 2026, 10 years 8 months after primary completion.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 8 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2014
First posted
Nov 20, 2014
StartActual
Nov 21, 2014
Primary completionActual
Aug 13, 2015
CompletionActual
Aug 13, 2015
Results first posted
Apr 22, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02296411
Responsible party
Sponsor
First posted
Nov 20, 2014
Start date
Nov 21, 2014
Primary completion
Aug 13, 2015
Completion
Aug 13, 2015
Results posted
Apr 22, 2026
Last update
Apr 22, 2026

Study contacts

prof. Pierluigi Paggiaro, MD
principal investigator · Dip. Cardio-Toracico e Vascolare Malattie dell'Apparato respiratorio, Ospedale Cisanello, Pisa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion